← Back to Search

Cancer Diagnostic Device

EsoGuard for Barrett's Esophagus (ESOGUARDBE1 Trial)

N/A
Waitlist Available
Research Sponsored by Lucid Diagnostics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
Awards & highlights

Summary

This trial uses the EsoGuard test and EsoCheck device to screen high-risk individuals for Barrett's Esophagus and esophageal cancer by collecting and testing cells from the esophagus.

Eligible Conditions
  • Barrett's Esophagus
  • Esophageal Cancer

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~cross-sectional point in time per subject through study completion which is up to approximately 5 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and cross-sectional point in time per subject through study completion which is up to approximately 5 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Primary Efficacy
Secondary outcome measures
Secondary Efficacy
Other outcome measures
Safety of EsoCheck device administration

Trial Design

1Treatment groups
Experimental Treatment
Group I: EsoCheck vs. EGD with or without biopsiesExperimental Treatment1 Intervention
All subjects will undergo both the EsoCheck (non-invasive esophageal cell sample collection) followed by EGD (with or without biopsies)
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
EsoGuard
2020
N/A
~150

Find a Location

Who is running the clinical trial?

Lucid Diagnostics, Inc.Lead Sponsor
5 Previous Clinical Trials
1,582 Total Patients Enrolled
Randy Brown, MSStudy DirectorLucid Diagnostics
Michelle McDermottStudy DirectorLucid Diagnostics
1 Previous Clinical Trials
470 Total Patients Enrolled
~26 spots leftby Sep 2025